Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial |
| |
Authors: | Kentaro Sugano Yasushi Matsumoto Tsukasa Itabashi Sumihisa Abe Nobuhiro Sakaki Kiyoshi Ashida Yuji Mizokami Tsutomu Chiba Shigeyuki Matsui Tatsuya Kanto Kazuyuki Shimada Shinichiro Uchiyama Naomi Uemura Naoki Hiramatsu |
| |
Affiliation: | Division of Gastroenterology, Department of Internal Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. sugano@jichi.ac.jp |
| |
Abstract: | Background The efficacy of low-dose lansoprazole has not been established for the prevention of recurrent gastric or duodenal ulcers in those receiving long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular protection. This study sought to examine the efficacy of low-dose lansoprazole (15?mg once daily) for the secondary prevention of LDA-associated gastric or duodenal ulcers. Methods Patients were randomized to receive lansoprazole 15?mg daily (n?=?226) or gefarnate 50?mg twice daily (n?=?235) for 12?months or longer in a prospective, multicenter, double-blind, randomized active-controlled trial, followed by a 6-month follow-up study with open-label lansoprazole treatment. The study utilized 94 sites in Japan and 461 Japanese patients with a history of gastric or duodenal ulcers who required long-term LDA therapy for cardiovascular and cerebrovascular disease. Results The primary endpoint was the development of gastric or duodenal ulcers. The cumulative incidence of gastric or duodenal ulcers on days 91, 181, and 361 from the start of the study was calculated by the Kaplan?CMeier method as 1.5, 2.1, and 3.7%, respectively, in the lansoprazole group versus 15.2, 24.0, and 31.7%, respectively, in the gefarnate group. The risk of ulcer development was significantly (log-rank test, P?0.001) lower in the lansoprazole group than in the gefarnate group, with the hazard ratio being 0.099 (95% confidence interval [CI] 0.042?C0.230). Conclusion Lansoprazole was superior to gefarnate in reducing the risk of gastric or duodenal ulcer recurrence in patients with a definite history of gastric or duodenal ulcers who required long-term LDA therapy. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|